Ideas in this flowchart

• Dendritic cell (DC)-based vaccines represent a strategy for cancer treatment.
• Clinical studies are evaluating DC vaccines in different cancer settings.
• A pilot study involved patients with early-stage HER2-positive breast cancer.
• Patients received an injected DC vaccine targeting HER2 before chemotherapy.
• The HER2-targeting vaccine was safe and immunologically active.
• It increased T-cell infiltration in tumors and potentially enhanced complete response rates.
• Another trial is testing a DC vaccine in patients with pancreatic cancer.
• The pancreatic cancer vaccine uses personalized mutant KRAS peptides.
• The trial demonstrates feasibility for this vaccination approach.
• It lays the foundation for further study of DC vaccines in one of the deadliest cancer types.